Ads
related to: er positive her2 positive treatmentcancer.ucihealth.org has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
ER-positive is one of the Receptor statuses identified in the classification of breast cancer.Receptor status was traditionally considered by reviewing each individual receptor (ER, PR, her2) in turn, but newer approaches look at these together, along with the tumor grade, to categorize breast cancer into several conceptual molecular classes that have different prognoses and may have different ...
One review characterized these genetic tests collectively as adding "modest prognostic information for patients with HER2-positive and triple-negative tumors, but when measures of clinical risk are equivocal (e.g., intermediate expression of ER and intermediate histologic grade), these assays could guide clinical decisions".
The overexpression of HER2 is determined by immunohistochemistry (IHC), or with fluorescent in situ hybridization in those equivocal cases where IHC does not provide a clear result. Different molecular subtypes of breast cancer have also been described, which loosely align with receptor status: Luminal A (ER and/or PR positive; HER2 negative)
As a drug target. HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [ 33]
For those whose tumors are HER2-positive, adding the HER2-targeted antibody trastuzumab to chemotherapy reduces the chance of cancer recurrence and death by at least a third. [63] [64] Trastuzumab is given weekly or every three weeks for twelve months. [64] Adding a second HER2-targeted antibody, pertuzumab slightly enhances treatment efficacy ...
HER2-positive tumors may be treated with the targeted medical therapy (e.g., trastuzumab). Further information: Breast cancer management and Breast cancer § Management Treatment of non-metastatic invasive breast cancer can vary based on staging, usually early stage (stages I and II) versus locally advanced (stage III).
Ads
related to: er positive her2 positive treatmentcancer.ucihealth.org has been visited by 10K+ users in the past month